Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 2
2009 2
2010 1
2011 4
2012 3
2013 2
2014 2
2016 2
2017 2
2018 1
2019 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.
Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N, Morel H, Duval Y, Asselain B, Letierce A, Trédaniel J, Auliac JB, Bylicki O, Moreau L, Fore M, Corre R, Couraud S, Cortot A; Study Group KBP-2020-CPHG; KBP-2020-CPHG. Debieuvre D, et al. Lancet Reg Health Eur. 2022 Aug 29;22:100492. doi: 10.1016/j.lanepe.2022.100492. eCollection 2022 Nov. Lancet Reg Health Eur. 2022. PMID: 36108315 Free PMC article.
[Spontaneous regression of a pulmonary adenocarcinoma].
Dujon C, Glaser C, Azarian R, Petitpretz P. Dujon C, et al. Rev Mal Respir. 2017 Jan;34(1):86-88. doi: 10.1016/j.rmr.2016.04.025. Epub 2016 Jun 3. Rev Mal Respir. 2017. PMID: 27266898 French. No abstract available.
Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.
Talb J, Takam Kamga P, Mayenga M, Costantini A, Julié C, Dumenil C, Dumoulin J, Ouaknine J, Giraud V, Dujon C, Azarian R, Glaser C, Emile JF, Giroux Leprieur E. Talb J, et al. Among authors: dujon c. Cancer Immunol Immunother. 2022 Nov;71(11):2791-2799. doi: 10.1007/s00262-022-03206-4. Epub 2022 Apr 18. Cancer Immunol Immunother. 2022. PMID: 35435450 Free PMC article.
High-risk patients following hospitalisation for an acute exacerbation of COPD.
Piquet J, Chavaillon JM, David P, Martin F, Blanchon F, Roche N; French College of General Hospital Respiratory Physicians (CPHG). Piquet J, et al. Eur Respir J. 2013 Oct;42(4):946-55. doi: 10.1183/09031936.00180312. Epub 2013 Jan 24. Eur Respir J. 2013. PMID: 23349446 Free article.
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E. Mehlman C, et al. Among authors: dujon c. Lung Cancer. 2019 Nov;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. Epub 2019 Sep 28. Lung Cancer. 2019. PMID: 31600593
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O. Delanoy N, et al. Among authors: dujon c. Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4. Lancet Haematol. 2019. PMID: 30528137
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Corre R, Greillier L, Le Caër H, Audigier-Valette C, Baize N, Bérard H, Falchero L, Monnet I, Dansin E, Vergnenègre A, Marcq M, Decroisette C, Auliac JB, Bota S, Lamy R, Massuti B, Dujon C, Pérol M, Daurès JP, Descourt R, Léna H, Plassot C, Chouaïd C. Corre R, et al. Among authors: dujon c. J Clin Oncol. 2016 May 1;34(13):1476-83. doi: 10.1200/JCO.2015.63.5839. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884557 Clinical Trial.
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Chouaid C, Le Caer H, Corre R, Crequit J, Locher C, Falchero L, Dujon C, Berard H, Monnet I, Vergnenegre A. Chouaid C, et al. Among authors: dujon c. Clin Lung Cancer. 2013 Mar;14(2):103-7. doi: 10.1016/j.cllc.2012.04.006. Epub 2012 Jun 7. Clin Lung Cancer. 2013. PMID: 22682669 Clinical Trial.
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Chouaid C, Le Caer H, Locher C, Dujon C, Thomas P, Auliac JB, Monnet I, Vergnenegre A; GFPC 0504 Team. Chouaid C, et al. Among authors: dujon c. BMC Cancer. 2012 Jul 20;12:301. doi: 10.1186/1471-2407-12-301. BMC Cancer. 2012. PMID: 22817667 Free PMC article. Clinical Trial.
25 results